ArticleEBioMedicine2026
Epigenome-wide analysis in West Africans identifies DNA methylation markers for circulating adiponectin.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdiponectin is a circulating adipokine involved in energy metabolism and inflammation, with reported protective effects against cardiometabolic diseases such as type 2 diabetes (T2D) and early kidney disease. However, its regulation remains poorly understood. This study aimed to identify epigenetic loci associated with adiponectin levels.
methodsDNA methylation was profiled using Illumina 450K and EPIC (850K) arrays in 315 Ghanaians (RODAM-Pros study) and 593 Nigerians (AADM study). Differentially methylated positions (DMPs) were identified using linear regression models adjusted for age, sex, BMI, blood cell proportions, and technical covariates. Analyses were stratified by T2D status and cohort, then meta-analysed to identify DMPs associated with adiponectin across T2D status (combining participants with-and-without diabetes). RNA-seq data on 77 blood, 49 subcutaneous adipose tissue (SAT), and 55 skeletal muscle samples from the AADM study were used to identify eQTMs for identified DMPs.
findingsWe identified three epigenome-wide significant DMPs: cg03546163 (Z-score = 5.76, p ≤ 0.001, 5'UTR of FKBP5), cg02561343 (Z-score = 5.11, p ≤ 0.001, within UST), and cg23969380 (Z-score = 5.13, p ≤ 0.001, ADGRD1 body). cg03546163 was an eQTM for PLA2G12B in SAT (beta = -0.039, FDR = 0.047), cg02561343 for PSMD8 (beta = -11.85, FDR = 0.029) and TECR (beta = -9.48, FDR = 0.029) in SAT, and cg23969380 for HIGD2AP1 (beta = -0.095, FDR = 0.024) in blood. These genes have been reported to be involved in lipid metabolism (PLA2G12B and TECR), proteasomal degradation (PSMD8), and cellular stress-responses (HIGD2AP1).
interpretationThis epigenome-wide study of adiponectin in sub-Saharan African populations identified DNA methylation loci potentially involved in adiponectin regulation through lipid-metabolism, inflammation, proteostasis, and stress-response pathways. These findings provide a foundation for replication and further investigation to improve understanding of the role of adiponectin in cardiometabolic-health.
fundingNational Institutes of Health and European Research Council.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.